Skip to the content
[email protected]
Get in Touch
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
Menu
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
[email protected]
Get in Touch
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
Menu
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
NEWS
NEWS
News
Highlights
News
2025
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
News
Highlights
News
2025
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
NEWS
NEWS
News
Highlights
News
2025
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
News
Highlights
News
2025
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
News Highlights
Check this page for recent news from Appili Therapeutics.
Members of the media can contact us
General inquiries, contact us
May 1, 2025
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
Read More
April 28, 2025
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
Read More
April 2, 2025
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Read More
March 18, 2025
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
Read More
February 14, 2025
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Read More
November 19, 2024
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
Read More
November 14, 2024
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Read More
November 6, 2024
Appili Therapeutics Announces Results of Special Meeting of Shareholders
Read More
October 31, 2024
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Read More
October 17, 2024
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
Read More
October 10, 2024
Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders
Read More
September 17, 2024
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Read More
August 21, 2024
Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt
Read More
August 13, 2024
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025
Read More
July 18, 2024
Appili Therapeutics Announces Second Amendment to Arrangement Agreement
Read More
July 2, 2024
Appili Therapeutics Announces Amendment to Arrangement Agreement and Increase to Bridge Loan
Read More
June 25, 2024
Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results
Read More
April 26, 2024
Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.
Read More
April 2, 2024
Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.
Read More
March 12, 2024
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
Read More
February 13, 2024
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
Read More
